LaunchTrends®: Inflectra/Remsima (Wave 1) is the first in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two different brands of Celltrion’s infliximab biosimilar CT-P13.

The study surveys rheumatologists and gastroenterologists in Germany, and in Wave 1, we include key insights from German payers/payer advisers. These reports evaluate physicians’ current awareness and perception of Inflectra/Remsima, their likely uptake over time, the biosimilars’ effect on other products in the same class, and promotional activity related to biosimilar and innovator infliximab.

Questions Answered:

  • Inflectra and Remsima launched in Germany in February 2015. Are German rheumatologists and gastroenterologists aware of the biosimilars and of how they were tested during clinical development?
  • Biosimilars are intended to share the clinical profile of the reference brand; therefore, a clinical benefit is not expected to be associated with their use. Why have physicians chosen to prescribe Inflectra/Remsima or an alternative biologic?
  • Pharmacists in Germany are not permitted to substitute a prescribed biologic brand for a biosimilar; thus, physicians must directly prescribe Inflectra/Remsima in order for their patients to receive it. What promotional messages are sales representatives using for Inflectra, Remsima, and Remicade in order to encourage physician prescribing?
  • Although physicians retain control over which biologic pharmacists will dispense to their patients, payers in Germany hold the power to influence physician prescribing behavior through prescribing targets and negotiation of rebate contracts. How have payers in Germany responded to the introduction of Inflectra/Remsima?


Markets covered: Germany.

Primary research: Online survey of 31 gastroenterologists and 35 rheumatologists in Germany; telephone interviews with two German payers.

Table of contents

  • Biosimilars - Emerging Biosimilars - Immunology: Inflectra/Remsima Launch Tracking (Germany) Wave 1
    • Key Findings
      • Familiarity and Awareness of Inflectra/Remsima
      • Inflectra/Remsima Trial and Use
      • Pressure to Use Biosimilars
      • Considerations for Future Biosimilar Entrants
      • Differences Between Biosimilar Prescribers and Nonprescribers: RA
        • Differences Between Biosimilar Prescribers and Nonprescribers: CD
        • Market Access Analysis
          • Background on Reimbursement in Germany
          • Biosimilars Pricing in Germany
          • List Price of Infliximab Products in Europe
            • German Pharmacy Retail Prices for Infliximab (5x100 mg)
          • Interviewed Payer Insights on Biosimilar Pricing in Germany
            • Select Quotes from Interviewed German Payers
          • Key Mechanisms to Promote Biosimilar Uptake in Germany
            • Interviewed Payer Insights on Prescribing Quotas
              • Select Quotes from Interviewed German Payers
            • Key Mechanisms to Promote Biosimilar Uptake in Germany
              • Interviewed Payer Insights on Rebate Contracts
                • Select Quotes from Interviewed German Payers

          Author(s): Marta Delgado

          Marta Delgado, Ph.D. is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a Ph.D. in Molecular Neuroscience from University College of London (UCL) and a B.Sc. in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.